Mellstedt et al., 1991 - Google Patents
Patients treated with a monoclonal antibody (ab1) to the colorectal carcinoma antigen 17–1A develop a cellular response (DTH) to the “internal image of the antigen” …Mellstedt et al., 1991
- Document ID
- 13925250820082255341
- Author
- Mellstedt H
- Frodin J
- Biberfeld P
- Fagerberg J
- Gisombe R
- Hernandez A
- Masucci G
- Li S
- Steinitz M
- Publication year
- Publication venue
- International journal of cancer
External Links
Snippet
The anti‐tumor effector functions of unconjugated MAb in cancer therapy are not fully understood. Direct cytotoxic mechanisms have been demonstrated as well as induction of anti‐idiotypic (ab2) and anti‐anti‐idiotypic (ab3) antibodies. If such a humoral response is …
- 239000000427 antigen 0 title abstract description 18
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
- C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
- C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
- C07K16/4266—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses, e.g. hepatitis E virus
- C07K16/1036—Retroviridae, e.g. leukemia viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody or an immunoglobulin, or a fragment thereof, e.g. a camelised human single domain antibody, or the Fc fragment of an antibody
- A61K51/1003—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody or an immunoglobulin, or a fragment thereof, e.g. a camelised human single domain antibody, or the Fc fragment of an antibody not used, see subgroups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Foon et al. | Immune response to the carcinoembryonic antigen in patients treated with an anti-idiotype antibody vaccine. | |
| Foon et al. | Clinical and immune responses in advanced colorectal cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen. | |
| Herlyn et al. | Anti-idiotypic antibodies bear the internal image of a human tumor antigen | |
| US5078998A (en) | Hybrid ligand directed to activation of cytotoxic effector T lymphocytes and target associated antigen | |
| US5053224A (en) | Induction of antibody response to solid tumors with anti-idiotype antibodies | |
| US20080131443A1 (en) | Method and composition for reconforming multi-epitopic antigens to intiate an immune response | |
| EP0141783B1 (en) | Immune response to tumours and viruses induced by anti-idiotype antibodies | |
| JPH07126300A (en) | Monoclonal antibody that recognizes specific antigen of human B cell receptor complex | |
| Raychaudhuri et al. | Tumor-specific idiotype vaccines. II. Analysis of the tumor-related network response induced by the tumor and by internal image antigens (Ab2 beta). | |
| CA2105477A1 (en) | Anti-idiotype antibodies to human melanoma-associated proteoglycan antigen | |
| Mellstedt et al. | Patients treated with a monoclonal antibody (ab1) to the colorectal carcinoma antigen 17–1A develop a cellular response (DTH) to the “internal image of the antigen”(ab2) | |
| Steinitz et al. | Human monoclonal anti-idiotypic antibodies. I. Establishment of immortalized cell lines from a tumor patient treated with mouse monoclonal antibodies. | |
| Chakraborty et al. | Induction of human breast cancer-specific antibody responses in cynomolgus monkeys by a murine monoclonal anti-idiotype antibody | |
| Samonigg et al. | Immune response to tumor antigens in a patient with colorectal cancer after immunization with anti-idiotype antibody | |
| Chatterjee et al. | Anti-idiotype monoclonal antibodies as vaccines for human cancer | |
| Chakraborty et al. | Preclinical evaluation in nonhuman primates of an anti-idiotypic antibody that mimicks the carcinoembryonic antigen | |
| CA2134751C (en) | Monoclonal antibodies and their use | |
| Barth et al. | Monoclonal anti‐idiotypic antibody mimicking a tumor‐associated sialoglycoprotein antigen induces humoral immune response against human small‐cell lung carcinoma | |
| Bhattacharya-Chatterjee et al. | Anti-idiotype antibody vaccine therapies of cancer | |
| US20090202560A1 (en) | Method for diagnosing efficacy of xenotypic antibody therapy | |
| US20020146410A1 (en) | Monoclonal antibodies and their use | |
| CA1341566C (en) | Immune response to tumors induced by anti-idiotype antibodies | |
| AU711270C (en) | Method and composition for reconforming multi-epitopic antigens to initiate an immune response | |
| Hanzawa et al. | Detection of xenogeneic anti-idiotypic antibodies specific to murine monoclonal antibody 17-1A in patients with gastrointestinal cancer | |
| NZ503032A (en) | Use of a binding agent to reconforming multi-epitopic antigens to initiate an immune response |